Literature DB >> 33425355

Pro-inflammatory dopamine-2 receptor-specific T cells in paediatric movement and psychiatric disorders.

Deepti Pilli1,2, Alicia Zou1,2, Ruebena Dawes2,3, Joseph A Lopez1,2, Fiona Tea1,2, Ganesha Liyanage1,4, Fiona Xz Lee1, Vera Merheb1, Samuel D Houston1,5, Aleha Pillay1, Hannah F Jones1,2, Sudarshini Ramanathan1,2, Shekeeb Mohammad1,2, Anthony D Kelleher6, Stephen I Alexander2,7, Russell C Dale1,2,8, Fabienne Brilot1,2,4,8.   

Abstract

OBJECTIVES: A dysregulated inflammatory response against the dopamine-2 receptor (D2R) has been implicated in movement and psychiatric disorders. D2R antibodies were previously reported in a subset of these patients; however, the role of T cells in these disorders remains unknown. Our objective was to identify and characterise pro-inflammatory D2R-specific T cells in movement and psychiatric disorders.
METHODS: Blood from paediatric patients with movement and psychiatric disorders of suspected autoimmune and neurodevelopmental aetiology (n = 24) and controls (n = 16) was cultured in vitro with a human D2R peptide library, and D2R-specific T cells were identified by flow cytometric quantification of CD4+CD25+CD134+ T cells. Cytokine secretion was analysed using a cytometric bead array and ELISA. HLA genotypes were examined in D2R-specific T-cell-positive patients. D2R antibody seropositivity was determined using a flow cytometry live cell-based assay.
RESULTS: Three immunodominant regions of D2R, amino acid (aa)121-131, aa171-181 and aa396-416, specifically activated CD4+ T cells in 8/24 patients. Peptides corresponding to these regions were predicted to bind with high affinity to the HLA of the eight positive patients and had also elicited the secretion of pro-inflammatory cytokines IL-2, IFN- γ, TNF, IL-6, IL-17A and IL-17F. All eight patients were seronegative for D2R antibodies.
CONCLUSION: Autoreactive D2R-specific T cells and a pro-inflammatory Th1 and Th17 cytokine profile characterise a subset of paediatric patients with movement and psychiatric disorders, further underpinning the theory of immune dysregulation in these disorders. These findings offer new perspectives into the neuroinflammatory mechanisms of movement and psychiatric disorders and can influence patient diagnosis and treatment.
© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.

Entities:  

Keywords:  autoimmune encephalitis; autoimmunity; dopamine‐2 receptor antibodies; neurodevelopmental disorders; pro‐inflammatory T cells

Year:  2020        PMID: 33425355      PMCID: PMC7780098          DOI: 10.1002/cti2.1229

Source DB:  PubMed          Journal:  Clin Transl Immunology        ISSN: 2050-0068


  103 in total

Review 1.  Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases.

Authors:  M Levite
Journal:  Acta Physiol (Oxf)       Date:  2015-09-24       Impact factor: 6.311

2.  D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4+ -T cells.

Authors:  Eva-Maria Boneberg; Elisabeth von Seydlitz; Karl Pröpster; Hans Watzl; Brigitte Rockstroh; Harald Illges
Journal:  J Neuroimmunol       Date:  2005-12-27       Impact factor: 3.478

Review 3.  Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea.

Authors:  Christine A Kirvan; Susan E Swedo; David Kurahara; Madeleine W Cunningham
Journal:  Autoimmunity       Date:  2006-02       Impact factor: 2.815

4.  Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis.

Authors:  Verena Brucklacher-Waldert; Klarissa Stuerner; Manuela Kolster; Julia Wolthausen; Eva Tolosa
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

Review 5.  Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.

Authors:  Ilya Ayzenberg; Ingo Kleiter; Alexandra Schröder; Kerstin Hellwig; Andrew Chan; Takashi Yamamura; Ralf Gold
Journal:  JAMA Neurol       Date:  2013-03-01       Impact factor: 18.302

6.  Polymorphism of HLA-DRB1, -DQB1 and -DPB1 genes in Bai ethnic group in southwestern China.

Authors:  W Hu; L Tang; J Wang; B Wang; S Li; H Yu; W Tang; H Li; S Tan; W Shou; C Xiao
Journal:  Tissue Antigens       Date:  2008-09-05

7.  Brain human monoclonal autoantibody from sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor: implications in human disease.

Authors:  Carol J Cox; Meenakshi Sharma; James F Leckman; Jonathan Zuccolo; Amir Zuccolo; Abraham Kovoor; Susan E Swedo; Madeleine W Cunningham
Journal:  J Immunol       Date:  2013-11-01       Impact factor: 5.422

8.  Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.

Authors:  Woo-Jin Lee; Soon-Tae Lee; Jangsup Moon; Jun-Sang Sunwoo; Jung-Ick Byun; Jung-Ah Lim; Tae-Joon Kim; Yong-Won Shin; Keon-Joo Lee; Jin-Sun Jun; Han Sang Lee; Soyun Kim; Kyung-Il Park; Keun-Hwa Jung; Ki-Young Jung; Manho Kim; Sang Kun Lee; Kon Chu
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 9.  Autoimmune Encephalitides: A Broadening Field of Treatable Conditions.

Authors:  Bernadette Kalman
Journal:  Neurologist       Date:  2017-01       Impact factor: 1.398

10.  Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism.

Authors:  Kathleen Connery; Marie Tippett; Leanna M Delhey; Shannon Rose; John C Slattery; Stephen G Kahler; Juergen Hahn; Uwe Kruger; Madeleine W Cunningham; Craig Shimasaki; Richard E Frye
Journal:  Transl Psychiatry       Date:  2018-08-10       Impact factor: 6.222

View more
  1 in total

Review 1.  Cytokine profile of pediatric patients with obsessive-compulsive and/or movement disorder symptoms: A review.

Authors:  Rebecca Alison Fabricius; Camilla Birgitte Sørensen; Liselotte Skov; Nanette Mol Debes
Journal:  Front Pediatr       Date:  2022-08-19       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.